Rheumatoid Arthritis Treatment Market Analysis

The market is segmented based on drug class into disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, uric acid drugs, and others. The disease-modifying anti-rheumatic drugs (DMARDs) segment is anticipated to grab the most significant share by the end of 2021 on account of the increase in the adoption of DMARDs as a first-line treatment for rheumatoid arthritis. These drugs control the progression of rheumatoid arthritis, and provide quick relief as compared to other medications. 

Based on end-user, the retail pharmacy segment in the rheumatoid arthritis treatment market is projected to grow with a notable CAGR over the forecast period. The segment's growth can be attributed to the easy access of drugs in retail pharmacy for the general population. Moreover, the trend for taking online orders by retail pharmacies increases and is estimated to result in segment growth. Additionally, online pharmacy is also expected to grow during the forecast period due to the growing internet penetration and adoption of e-commerce services.  

Our in-depth analysis of the global market includes the following segments